GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Pangaea Oncology SA (XMAD:PANG) » Definitions » 3-Year EPS without NRI Growth Rate

Pangaea Oncology (XMAD:PANG) 3-Year EPS without NRI Growth Rate : 16.50% (As of Jun. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Pangaea Oncology 3-Year EPS without NRI Growth Rate?

Pangaea Oncology's EPS without NRI for the six months ended in Jun. 2023 was €-0.03.

During the past 3 years, the average EPS without NRI Growth Rate was 16.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was 19.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 10 years, the highest 3-Year average EPS without NRI Growth Rate of Pangaea Oncology was 41.10% per year. The lowest was -96.20% per year. And the median was -9.80% per year.


Competitive Comparison of Pangaea Oncology's 3-Year EPS without NRI Growth Rate

For the Diagnostics & Research subindustry, Pangaea Oncology's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pangaea Oncology's 3-Year EPS without NRI Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Pangaea Oncology's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Pangaea Oncology's 3-Year EPS without NRI Growth Rate falls into.



Pangaea Oncology 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Pangaea Oncology  (XMAD:PANG) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Pangaea Oncology 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Pangaea Oncology's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Pangaea Oncology (XMAD:PANG) Business Description

Traded in Other Exchanges
N/A
Address
Calle Sabino Arana, 5-19, Barcelona, ESP, 08028
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.

Pangaea Oncology (XMAD:PANG) Headlines

No Headlines